Edition:
United States

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

3.56USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.56
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,991
52-wk High
$7.75
52-wk Low
$2.65

Latest Key Developments (Source: Significant Developments)

Caladrius Biosciences reports 2017 third quarter results
Thursday, 9 Nov 2017 04:11pm EST 

Nov 9 (Reuters) - Caladrius Biosciences Inc :Caladrius Biosciences reports 2017 third quarter results.Q3 loss per share $0.38 from continuing operations.  Full Article

Caladrius Biosciences files for resale of co's common stock‍​ by the selling stockholders
Wednesday, 6 Sep 2017 06:01am EDT 

Sept 6 (Reuters) - Caladrius Biosciences Inc :Files for resale of up to 932,204 shares of Co's common stock‍​ by the selling stockholders - SEC filing.  Full Article

Caladrius Biosciences Q2 loss per share $0.22 from continuing operations
Thursday, 10 Aug 2017 04:05pm EDT 

Aug 10 (Reuters) - Caladrius Biosciences Inc :Caladrius Biosciences reports 2017 second quarter results.Q2 loss per share $0.22 from continuing operations.  Full Article

Caladrius Biosciences says 50 pct of subjects have been treated in the phase 2 clinical trial of CLBS03
Wednesday, 19 Jul 2017 08:00am EDT 

July 19 (Reuters) - Caladrius Biosciences Inc ::Caladrius Biosciences announces that 50 pct of subjects have been treated in the phase 2 clinical trial of clbs03 for type 1 diabetes.Caladrius - interim analysis of early therapeutic effect to occur after 6 month post-treatment follow-up visit,results in late 2017/early 2018.  Full Article

Caladrius Biosciences Q1 loss per share $1.12
Monday, 15 May 2017 05:07pm EDT 

May 15 (Reuters) - Caladrius Biosciences Inc :Caladrius Biosciences announces 2017 first quarter financial results.Q1 revenue rose 6 percent to $7.9 million.Q1 loss per share $1.12.Expects to provide more specifics on cash usage for balance of 2017 after closing of Hitachi transaction.  Full Article

Caladrius Biosciences Inc says addition of four clinical sites for ongoing phase 2 study of CLBS03 in T1D
Monday, 3 Apr 2017 07:30am EDT 

Caladrius Biosciences Inc : Caladrius Biosciences Inc says addition of four clinical sites, including Joslin Diabetes Center, for ongoing phase 2 study of CLBS03 in T1D . Caladrius Biosciences Inc says expects to reach important milestone of treating 50% of subjects by mid-2017 .Caladrius Biosciences Inc says enrollment of 70(th) subject in study, expected to occur in mid-2017, will trigger an additional infusion of capital.  Full Article

Caladrius Biosciences awarded $12.2 mln grant from CIRM supporting Phase 2 trial of CLBS03
Thursday, 23 Feb 2017 01:44pm EST 

Caladrius Biosciences Inc : Caladrius Biosciences awarded $12.2 million grant from CIRM in support of Phase 2 clinical trial of CLBS03 to treat type 1 diabetes . Patients are currently being enrolled in second cohort of Phase 2 trial for CLBS03 . Interim analysis of Phase 2 trial for CLBS03's early therapeutic effect expected by end of 2017 .Grant is to cover expenses including manufacturing, development based in California, and other costs for Phase 2 trial for CLBS03.  Full Article

Caladrius Biosciences announces addition of three clinical sites
Wednesday, 25 Jan 2017 07:30am EST 

Caladrius Biosciences Inc : Caladrius Biosciences announces addition of three clinical sites, including university of California, San Francisco, for the ongoing Phase 2 study of CLBS03 in T1D . Caladrius Biosciences Inc - expects to reach milestone of treating 50 pct of subjects by mid-2017 for ongoing Phase 2 study of CLBS03 in T1D . Caladrius Biosciences - clinical sites will contribute to continued enrollment of subjects in Phase 2 clinical trial of CLBS03 to meet total of 111 .T-Rex study is expected to include approximately 12 U.S. study sites.  Full Article

Caladrius biosciences begins second cohort of mid-stage trial for treating diabetes
Monday, 31 Oct 2016 07:30am EDT 

Caladrius Biosciences Inc - : Caladrius Biosciences has modified T-rex study protocol to allow for an earlier than planned resumption of enrollment for remaining patients based on DSMB recommendation . Company now expects to reach milestone of treating 50% of subjects by mid-2017 .Caladrius Biosciences begins enrollment of second cohort of phase 2 trial of clbs03 as a treatment for type 1 diabetes following favorable safety data from first cohort.  Full Article

Newhall Construction posts 13.48 pct passive stake in Caladrius Biosciences as of Sept. 14 - SEC Filing
Monday, 26 Sep 2016 05:39pm EDT 

Caladrius Biosciences Inc:Newhall Construction Limited reports 13.48 percent passive stake in Caladrius Biosciences Inc, as of September 14, 2016 - SEC Filing.  Full Article

BRIEF-Caladrius Biosciences reports 2017 third quarter results

* Q3 loss per share $0.38 from continuing operations Source text for Eikon: Further company coverage: